Productivity assessment in Roche’s R&D following Genentech 2009 acquisition

Abstract

With an unprecedented mergers and acquisitions boom taking place in a pharmaceutical industry suffering rocketing development cost and a stagnation in the number of new medicines reaching the market, this dissertation provides insight on the extent to which this deal-making trend has consequences on R&D productivity. This analysis is focused on 2009 Roche’s acquisition of Genentech and shows the evolution of 6 key R&D metrics in a time frame that includes the years preceding and following the transaction. It identifies the signals given in terms of trends, which are instrumental to understand the transaction consequences on R&D activity. Evidence has been found that suggests an overall positive impact. Nevertheless, it is still necessary to continue tracking this particular case to assess if there is consistency in the trends and identify which might be the key success factors. Moreover, the relationship between the two companies involved and their R&D strategic direction is discussed.

Date of Award	18 Feb 2016
Original language	English
Awarding Institution	Universidade Católica Portuguesa
Supervisor	Susana Frazão Ferreira Fernandes Pinheiro (Supervisor)